A Look At Veracyte (VCYT) Valuation After Strong 2025 Update And 2026 Growth Guidance

Veracyte (VCYT) shares are in focus after the company released preliminary 2025 results alongside fresh guidance for 2026, outlining expected revenue ranges, testing growth and margin targets that give investors more visibility.

See our latest analysis for Veracyte.

Veracyte shares have been volatile around the recent guidance, with a 3.35% 1 day share price return to US$43.45 and a 24.93% 90 day share price return. The 1 year total shareholder return of 5.82% contrasts with a 62.80% total shareholder return over three years, suggesting momentum has cooled but interest around the new outlook is still influencing sentiment.

If Veracyte’s update has you thinking about other opportunities in diagnostics, it could be a good moment to scan healthcare stocks that might fit your portfolio goals.

With Veracyte trading at US$43.45, at a discount to both some analyst targets and certain intrinsic value estimates, the key question is whether this is a genuine opportunity or if the market is already pricing in future growth.

Most Popular Narrative: 8.5% Undervalued

Veracyte’s most followed narrative puts fair value at US$47.50 versus the recent US$43.45 close, so the story hinges on whether future execution matches those expectations.

Investments in automation, next-generation sequencing platforms (e.g., NovaSeq X), and data analytics, combined with strategic restructuring (SAS sale), are driving operational efficiencies and lower cost of goods, which is translating into improving gross margins and higher long-term profitability. Increasing clinical evidence, integration of AI/digital pathology, partnerships (Helix, biopharma), and a growing GRID/data platform are enhancing Veracyte's technology differentiation and providing leverage to value-based healthcare models. This strengthens the reimbursement outlook and competitive edge, supporting higher sustainable margins and earnings growth as volumes scale.

Read the complete narrative.

Curious how that efficiency story turns into a higher price tag? The narrative leans on compounded revenue growth, richer margins and a punchy future earnings multiple. Want to see how those pieces fit together and what kind of earnings profile they imply by the late 2020s?

Result: Fair Value of $47.50 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, that story could fray if payer coverage for key tests like Decipher and Afirma disappoints, or if larger rivals gain ground in AI driven cancer diagnostics.

Find out about the key risks to this Veracyte narrative.

Another View: Earnings Multiple Flags a Rich Price Tag

So far the story has leaned on future cash flows and a fair value around US$47.50, yet Veracyte’s current P/E of 113.3x tells a very different story. That compares with 21.1x for the US Biotechs industry, 64.6x for peers, and a fair ratio of 24x that our work suggests the market could move toward over time.

In plain terms, the share price currently bakes in a lot of future success, which raises the risk that any stumble in growth, margins or sentiment could hit the multiple harder than the business itself. If cash flow models point to upside while the P/E looks stretched, which signal do you trust more?

See what the numbers say about this price — find out in our valuation breakdown.

Build Your Own Veracyte Narrative

If parts of this story do not sit right with you, or you simply prefer to weigh the numbers yourself, you can test your own assumptions and build a fresh view in just a few minutes with Do it your way

A great starting point for your Veracyte research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.

Looking for more investment ideas?

If Veracyte has caught your attention, do not stop here. Broaden your watchlist with a few focused stock ideas that could help inform your next move.

• Target potential mispricing by scanning these 883 undervalued stocks based on cash flows where current prices may sit below what underlying cash flows suggest.
• Explore the AI theme by checking out these 25 AI penny stocks that connect real earnings potential with artificial intelligence related businesses.
• Review these 12 dividend stocks with yields > 3% for companies that offer yields above 3% and may suit income focused portfolios.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com